{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=elotuzumab&page=2", "query": { "intervention": "elotuzumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 54, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=elotuzumab&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=elotuzumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T03:41:15.969Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02969837", "title": "Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2017-07-10", "completion_date": "2025-12-01", "has_results": true, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 3, "location_summary": "Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02969837" }, { "nct_id": "NCT07555938", "title": "Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2026-06-23", "completion_date": "2033-01-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 9, "location_summary": "Duarte, California • Irvine, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07555938" }, { "nct_id": "NCT03651128", "title": "Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "bb2121", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2019-04-16", "completion_date": "2026-04-13", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03651128" }, { "nct_id": "NCT02420860", "title": "Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic Cell Transplantation Recipient", "Plasma Cell Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2015-04-14", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420860" }, { "nct_id": "NCT01239797", "title": "Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Dexamethasone (Oral)", "type": "DRUG" }, { "name": "Dexamethasone (IV)", "type": "DRUG" }, { "name": "Elotuzumab (BMS-901608; HuLuc63)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 646, "start_date": "2011-06-20", "completion_date": "2021-04-21", "has_results": true, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 63, "location_summary": "Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Corona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01239797" }, { "nct_id": "NCT04614636", "title": "FT538 in Subjects With Advanced Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "AML, Adult", "Multiple Myeloma", "Myeloma" ], "interventions": [ { "name": "FT538", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-10-17", "completion_date": "2023-08-08", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 8, "location_summary": "Denver, Colorado • Minneapolis, Minnesota • St Louis, Missouri + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04614636" }, { "nct_id": "NCT02719613", "title": "Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2016-07-15", "completion_date": "2026-02-23", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 14, "location_summary": "Tucson, Arizona • Bakersfield, California • Fountain Valley, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02719613" }, { "nct_id": "NCT05560399", "title": "A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Iberdomide", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-02-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05560399" }, { "nct_id": "NCT02718833", "title": "A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2016-06-21", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718833" }, { "nct_id": "NCT03019666", "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Mantle-Cell Lymphoma", "Follicular Lymphoma", "Indolent B Cell Lymphoma", "Primary Mediastinal Lymphoma", "Lymphoplasmacytic Lymphoma" ], "interventions": [ { "name": "Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2017-10-18", "completion_date": "2022-08-15", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-10-04T03:41:15.969Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03019666" } ] }